Howard Weiner Net Worth

Howard Weiner biography

Dr. Howard L. Weiner serves as Independent Director of the Company. Dr. Weiner, the Robert L. Kroc Professor of Neurology at the Harvard Medical School since 1997 and Co-Director of the Center for Neurologic Diseases at the Brigham & Women’s Hospital since 1985, pioneered the use of immunotherapy for the treatment of multiple sclerosis and has investigated immune abnormalities in the disease. He also pioneered the use of the mucosal immune system for the treatment of autoimmune and other diseases, including Alzheimer’s disease and Lou Gehrig’s disease. Based on his work, vaccines are being tested in multiple sclerosis, diabetes, and most recently in Alzheimer’s disease. Dr. Weiner attended Dartmouth College, and received his M.D. from the University of Colorado School of Medicine. Dr. Weiner provides significant medical expertise and clinical experience to our Board of Directors. For these reasons, we believe he is well qualified to serve on our Board of Directors.

What is the salary of Howard Weiner?

As the Independent Director of vTv Therapeutics Inc, the total compensation of Howard Weiner at vTv Therapeutics Inc is $58,595. There are 6 executives at vTv Therapeutics Inc getting paid more, with Stephen Holcombe having the highest compensation of $832,803.

How old is Howard Weiner?

Howard Weiner is 75, he's been the Independent Director of vTv Therapeutics Inc since 2019. There are no older and 7 younger executives at vTv Therapeutics Inc.

What's Howard Weiner's mailing address?

Howard's mailing address filed with the SEC is C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, SUITE 310, HIGH POINT, NC, 27265.

Insiders trading at vTv Therapeutics Inc

Over the last 9 years, insiders at vTv Therapeutics Inc have traded over $100,050 worth of vTv Therapeutics Inc stock and bought 38,545,137 units worth $116,272,024 . The most active insiders traders include Ronald O Perelman, Srinivas Akkaraju, eBros. Advisors Lp667, L.P.B.... On average, vTv Therapeutics Inc executives and independent directors trade stock every 33 days with the average trade being worth of $6,926,668. The most recent stock trade was executed by John A Fry on 28 November 2022, trading 61,000 units of VTVT stock currently worth $50,630.

What does vTv Therapeutics Inc do?

vtv therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of human therapeutics to fill unmet medical needs. our mission is to utilize our innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines. we have a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, diabetes and metabolic disorders, inflammation and cancer.

vTv Therapeutics Inc executives and stock owners

vTv Therapeutics Inc executives and other stock owners filed with the SEC include:

• Stephen Holcombe,
  President, Chief Executive Officer
• Rudy Howard,
  Chief Financial Officer, Executive Vice President
• Robin E. Abrams,
  Exec. Chairwoman of the Board
• Jeffrey Kindler,
  Chairman of the Board
• Noel Spiegel,
  Independent Director
• John Fry,
  Independent Director
• Howard Weiner,
  Independent Director
• Hersh Kozlov,
  Director
• Richard Nelson,
  Director
• Dr. Samuel B. Rollins Ph.D., J.D.,
  Sr. VP of Intellectual Property
• Dr. Robert C. Andrews Ph.D.,
  Sr. VP of Chemistry, Pharmaceutical Devel. and Quality
• Dr. Aaron H. Burstein,
  Sr. VP of Clinical Devel.
• Erin McDade,
  Chief of Staff
• David M. Lambert III,
  Sr. VP & Gen. Counsel
• Vanessa McDade,
  Chief Admin. Officer
• Dr. Carmen Valcarce Ph.D.,
  Chief Scientific Officer & Exec. VP
• Barry Brown,
  VP of Fin.
• Deepa Prasad,
  Pres, CEO & Director
• Daniel K Spiegelman,
  Director
• Paul G Savas,
  Director
• Steven Michael Cohen,
  Director
• Craig C Parker,
  Director
• Fahed Al Marzooqi,
  Director
• Larry Douglas Altstiel,
  Chief Medical Officer
• Srinivas Akkaraju,
  
• Jonathan Isaacsohn,
  Director
• Rich S. Nelson,
  Acting Chief Executive Officer
• Ronald O Perelman,
  10% owner
• Deepa Prasad,
  President and CEO
• Keith R. Harris,
  Director
• Steven L. Tuch,
  Chief Financial Officer
• Bros. Advisors Lp667, L.P.B...,
  
• Paul J Sekhri,
  President and CEO
• Anne M. Phillips,
  Director